Favorable outcome of severe, extensive, granulocyte colony-stimulating factor-induced, corticosteroid-resistant Sweet's syndrome treated with high-dose intravenous immunoglobulin.

Authors :: Calixto R
Menezes Y
Ostronoff M
Sucupira A
Botelho LF
Florencio R
Martins M
Souto Maior AP
Source :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Feb 10; Vol. 32 (5), pp. e1-2. Date of Electronic Publication: 2014 Jan 06.
Publication Year :: 2014

Subjects :: Adult
Biopsy
Humans
Male
Multiple Myeloma diagnosis
Remission Induction
Severity of Illness Index
Skin pathology
Sweet Syndrome chemically induced
Sweet Syndrome diagnosis
Treatment Outcome
Adrenal Cortex Hormones therapeutic use
Antineoplastic Agents adverse effects
Drug Resistance
Granulocyte Colony-Stimulating Factor adverse effects
Immunoglobulins, Intravenous therapeutic use
Multiple Myeloma drug therapy
Skin drug effects
Sweet Syndrome drug therapy

Language :: English
ISSN :: 1527-7755
Volume :: 32
Issue :: 5
Database :: MEDLINE
Journal :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Type :: Academic Journal
Accession number :: 24395855
Full Text :: https://doi.org/10.1200/JCO.2011.40.3212

Full Text Access

Tools